# Orchard Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orchard-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.orchard-tx.com/
- Total disclosed funding: $285M
- Latest round: Series C (Aug 2, 2018)
- Investors on record: 22

## About

Based in London, UK, and founded in 2015 Orchard Therapeutics Limited is a biopharmaceutical company that develops ex vivo gene therapy using patients ' externally modified blood stem cells and transplants them back into the body to correct the genetic disorder. It operates in three geographic regions: The United Kingdom, European Union, and the United States. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio. The company went public in October 2018 (Nasdaq: ORTX). In October 2023, Kyowa Kirin agreed to acquire Orchard Therapeutics PLC for approximately USD 387.40 million.

The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies.

The company's revenue is generated by conducting clinical trials and partners with advocates and organizations.

## Funding rounds

- Series C, Aug 2, 2018, $149M — Temasek Holdings, Venrock, Baillie Gifford, ArrowMark Partners, Driehaus Capital Management, Sphera Fund Management, Foresite Capital, Deerfield Management, RTW Investments, RA Capital Management, Cowen Inc., Cormorant Asset Management, Perceptive Advisors, Agent Capital, Ghost Tree Capital, Medison Ventures
- Series B, Mar 29, 2017, $106M — Temasek Holdings, Albion Capital, F-Prime Capital, Baillie Gifford, Pavilion Capital, RTW Investments, Cowen Inc., 4BIO Capital Partners, ORI Capital, Agent Capital, Juda Capital
- Series A, Feb 6, 2016, $30M — F-Prime Capital

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Temasek Holdings — Series B, Series C
- Albion Capital — Series B
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series B, Series C
- Pavilion Capital — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B, Series C
- Cowen Inc. — Series B, Series C
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Series B
- ORI Capital (https://capitalatlas.ai/funds/ori-capital) — Series B
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B, Series C
- Juda Capital — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C
- ArrowMark Partners — Series C
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series C
- Sphera Fund Management — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- Ghost Tree Capital — Series C
- Medison Ventures (https://capitalatlas.ai/funds/medison-ventures) — Series C